Combination treatment for advanced ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2, single-arm, open-label study evaluates the efficacy and safety of relacorilant in combination with nab-paclitaxel and bevacizumab for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. Participants will receive relacorilant orally for three consecutive days around nab-paclitaxel infusions, which are administered intravenously on specific days of a 28-day cycle. Bevacizumab will also be given intravenously every two weeks. The study aims to monitor treatment efficacy, safety, and tolerability until disease progression or unacceptable toxicity occurs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Arms A and B

* Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
* Arm A Only: Platinum-resistant disease
* Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
* Life expectancy of ≥3 months
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Able to swallow and retain oral medication
* 1 to 3 lines of prior systemic anticancer therapy
* Adequate organ function
* Negative pregnancy test for patients of childbearing potential

Arm C

* Stage III or IV, recurrent, or metastatic endometrial cancer
* Life expectancy of ≥3 months
* ECOG performance status of 0 or 1
* Able to swallow and retain oral medication
* Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD\[L\]1) antibody
* 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
* Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
* Adequate organ function
* Negative pregnancy test for patients of childbearing potential

Exclusion Criteria:

Arm A and B

* Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
* Prior enrollment in a clinical trial of relacorilant
* Prior anticancer therapy related toxicities not resolved to grade ≤1
* Any surgery within 4 weeks prior to enrollment
* Wide-field radiation to more than 25% of marrow-bearing areas
* Medical conditions requiring chronic or frequent treatment with corticosteroids
* Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
* Peripheral neuropathy from any cause \>Grade 1
* Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
* Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
* Bowel obstruction ≤12 weeks prior to study entry
* Ascites or pleural effusions requiring therapeutic paracentesis
* Untreated or symptomatic central nervous system metastases
* History of other malignancy within 3 years prior to enrollment
* Has received a live vaccine within 30 days prior to the study start date

Arm C

* Has progressed while receiving weekly paclitaxel or nab-paclitaxel
* Prior enrollment in a clinical trial of relacorilant
* Prior anticancer therapy related toxicities not resolved to grade ≤1
* Any surgery within 4 weeks prior to enrollment
* Wide-field radiation to more than 25% of marrow-bearing areas
* Medical conditions requiring chronic or frequent treatment with corticosteroids
* Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
* Peripheral neuropathy from any cause \>Grade 1
* Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
* Bowel obstruction ≤12 weeks prior to study entry
* Ascites or pleural effusions requiring therapeutic paracentesis
* History of other malignancy within 3 years prior to enrollment
* Has received a live vaccine within 30 days prior to the study start date
* Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.

Where it's running

• 004
  Birmingham, Alabama, United States Recruiting
• 150
  Palo Alto, California, United States Recruiting
• 014
  San Francisco, California, United States Recruiting
• 544
  Fort Myers, Florida, United States Recruiting
• 335
  Miami Beach, Florida, United States Recruiting
• 543
  West Palm Beach, Florida, United States Recruiting

Study contacts

• Study coordinator: Corcept Therapeutics
• Email: corceptstudy557@corcept.com
• Phone: 650-414-2314

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Testing PHST001 for advanced solid tumors

  This study is testing a new treatment called PHST001 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 20 sites Phase 1 Pheast Therapeutics · Beverly Hills, California and 19 other locations · NCT06840886

• Comparing two types of sutures for vaginal cuff closure in laparoscopic hysterectomy

  This study is testing whether a new type of suture can close the vaginal cuff faster than a standard suture for women having laparoscopic hysterectomy, without causing more complications.

  Recruiting at 2 sites Aesculap AG · Frankfurt am Main, Hesse and 1 other locations · NCT06024109

• HS-20089 treatment for ovarian and endometrial cancer

  This study is testing a new treatment called HS-20089 to see if it can help people with recurrent or advanced ovarian and endometrial cancer feel better.

  Recruiting at 26 sites Phase 2 Hansoh BioMedical R&D Company · Hefei, Anfei and 27 other locations · NCT06014190

• Registry development for patients with gynecologic cancer in Korea

  This study is collecting information from women with gynecologic cancers in Korea to see how their treatments and outcomes can be improved.

  Recruiting Asan Medical Center · Seoul · NCT05912972

• Testing a new drug called XMT-1660 for solid tumors

  This study is testing a new drug called XMT-1660 to see if it is safe and effective for people with hard-to-treat solid tumors like triple negative breast cancer and ovarian cancer.

  Recruiting at 26 sites Phase 1/2 Day One Biopharmaceuticals, Inc. · Phoenix, Arizona and 25 other locations · NCT05377996

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.